Annette Clancy
Chairman chez SWEDISH ORPHAN BIOVITRUM AB
Fortune : 90 719 $ au 31/03/2024
Profil
Annette V.
Clancy is currently the Chairman at Swedish Orphan Biovitrum AB, the Non-Executive Chairman at ENYO Pharma SA, and the Director at Abcd Ltd.
Previously, she served as the Chairman at Spark Therapeutics Ireland Ltd.
She was also the Chairman at ObsEva SA from 2013 to 2023.
Additionally, she held the position of Non-Executive Director at Silence Therapeutics Plc from 2008 to 2012 and at Weifa ASA from 2010 to 2013.
Ms. Clancy was an Independent Non-Executive Director at Lysogene SA in 2019.
Prior to that, she worked at GSK Plc from 1978 to 2008, where she held the position of Head-Transactions & Alliance Management.
Ms. Clancy obtained her undergraduate degree from the University of Bath.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 3 574 ( 0,00% ) | 89 312 $ | 31/03/2024 | |
OBSEVA SA
0,07% | 01/01/2023 | 97 500 ( 0,07% ) | 1 407 $ | 31/03/2024 |
Postes actifs de Annette Clancy
| Sociétés | Poste | Début |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Chairman | 05/01/2024 |
| Abcd Ltd. | Director/Board Member | - |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Chairman | - |
Anciens postes connus de Annette Clancy
| Sociétés | Poste | Fin |
|---|---|---|
| OBSEVA SA | Chairman | 10/03/2023 |
| LYSOGENE | Chairman | 22/05/2019 |
| WEIFA ASA | Director/Board Member | 21/05/2013 |
| SILENCE THERAPEUTICS PLC | Director/Board Member | 02/08/2012 |
| GSK PLC | Corporate Officer/Principal | 01/01/2008 |
Formation de Annette Clancy
| University of Bath | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| GSK PLC | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| OBSEVA SA | Health Technology |
| LYSOGENE | Commercial Services |
| Entreprise privées | 4 |
|---|---|
Weifa ASA
 Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
Spark Therapeutics Ireland Ltd.
 Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Health Technology |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Health Technology |
| Abcd Ltd. |
